Mitapivat-Pyrukynd officially launched in China

Mitapivat (mitapivat)-Pyrukynd is a new oral targeted drug for red blood cell pyruvate kinase deficiency and other inherited hemolytic anemias. It has been approved in overseas markets and is used to improve patients' anemia symptoms and reduce transfusion dependence. However, Metapival has not yet been officially launched in China, nor has it been included in the medical insurance catalog.

Because the R&D approval of drugs involves localized verification of clinical trial data, drug registration applications and policy approval processes, Chinese patients are temporarily unable to obtain original drugs through formal domestic channels. The expected time to market will depend on the drug registration process, the completion of domestic clinical trials and the speed of approval by the National Medical Products Administration (NMPA). It may still take several years for metapival to enter the Chinese market, especially considering factors such as the drug's rare disease indications, the complexity of clinical trials, and pricing and medical insurance inclusion evaluations.

During the period when the drug is not on the market, some patients may obtain the drug through overseas purchase or cross-border medical treatment, but this approach involves logistics, policy and price risks. Compared with overseas markets, if the drug is officially launched in China, drug prices and medical insurance inclusion policies will directly affect patient accessibility and treatment continuity. In the future, with the relaxation of China's rare disease drug approval policy and the country's attention to drugs for the treatment of hereditary hemolytic diseases, Metapival is expected to enter the domestic market and provide more patients with long-term and effective treatment options.

In summary, the official launch time of Metapival in China has not yet been determined. Patients should pay attention to the latest announcements from the drug regulatory authorities and domestic pharmaceutical companies, and at the same time explore temporary treatment options under the guidance of doctors, so that they can promptly switch to regular channels for use after the drug is approved for marketing, and achieve safe and effective long-term treatment.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd